(VIANEWS) – Shares of Novavax (NASDAQ: NVAX) slid 9.43% to $17.57 at 10:14 EST on Wednesday, after two consecutive sessions in a row of gains. NASDAQ is jumping 3.34% to $11,176.41, after two successive sessions in a row of gains. This seems, so far, a very up trend exchanging session today.
Novavax’s last close was $19.40, 91.8% below its 52-week high of $236.50.
Is Novavax Stock a Good Investment?
Several financial analysts have rated Novavax as a buy or a sell. The consensus of these analysts is a useful tool for evaluating stock performances. However, these recommendations should only be used in conjunction with other traditional stock analysis techniques. This includes technical analysis, earnings estimates, and various momentum models.
Novavax stock has risen 1,150% over the last three years. Its role in combating the current pandemic is expected to yield strong returns to shareholders. The company is also developing additional pre-clinical programs in infectious diseases, including Middle East respiratory syndrome.
Despite the stock’s recent price decline, Novavax’s stock may be a good buy if you’re a growth investor. Regulatory approvals of its Nuvaxovid vaccine could provide a strong catalyst for share price growth. In addition, the company recently announced a reverse stock split and sold manufacturing facilities to Catalent. However, there are still several risks associated with investing in Novavax.
Investing in Novavax stock isn’t an easy task. It’s a highly risky proposition, as there are few ways for it to gain value in the short term. However, bargain hunters and contrarian investors may be attracted to the stock. The company may be a bargain, despite analysts’ predictions of doom and gloom.
A company’s beta (beta) can be used to determine the risk level associated with it. The beta is a measure of its volatility in relation to the market. A beta of one indicates a low risk but a high beta value suggests high risk.
Novavax, Inc. is a biotechnology firm that focuses on vaccine development and commercialization. This company helps to address serious diseases such as HIV and other infectious disorders. Among the vaccine candidates are NVX–CoV2373, a candidate coronavirus vaccine, which is currently in 2 Phase III trials and 1 Phase IIb trial. NanoFlu is a candidate nanoparticle seasonal quadrivalent flu vaccine that is currently in Phase 3. ResVax is a candidate respiratory syncytial viral (RSV), fusion (F), protein nanoparticle vaccine. The company is currently developing RSV F vaccine, which is being tested in Phase II clinical trials for adults aged 60 years or older. It also has a Phase I clinical trial in pediatrics. Takeda Pharmaceutical Company Limited has signed a cooperation agreement for the production, commercialization, and development of NVXCoV2373 (a COVID-19 candidate vaccine). Novavax, Inc., was founded in 1987. It is located in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-7.27.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -238.6%.
Novavax’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.28%, a negative 2.36%, and a positive 5.71%, respectively.
Novavax’s highest amplitude of average volatility was 3.53% (last week), 5.82% (last month), and 5.71% (last quarter), respectively.
Novavax’s sales growth for the next quarter is 516%.
More news about Novavax (NVAX).